US Presidential Debates Begin: Pharma Is Favorite Villain – But Issues Focus Elsewhere
To no one’s surprise, attacks on the drug industry are a recurring and unifying theme for the Democratic Presidential candidates as they enter the debate cycle. But rhetoric aside, the health policy proposals getting the most airtime are more threatening for other sectors.
You may also be interested in...
President Trump isn’t going to let the Democrats own the drug pricing debate heading into the 2020 elections, so biopharma companies can look forward to many more headlines like the importation announcement on 31 July. When will it end?
Remarks to reporters prompt surprise and confusion among stakeholders and likely reflect the president’s impatience with the pace of regulatory and legislative pricing reforms.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.